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Abstract: Symptomatic and asymptomatic peripheral arterial disease (PAD) is a common 
problem in the elderly. The management of PAD includes the prevention of cardiovascular events 
and relief of symptoms – most commonly intermittent claudication (IC). Both require treatment 
of the causes and consequences of atherothrombosis, but some strategies are more effective for 
prevention of cardiovascular events and others are more effective for the relief of symptoms. 
Priorities for the prevention of cardiovascular events include smoking cessation, exercise, 
antiplatelet therapy, and the treatment of dyslipidemia, hypertension, and diabetes. Walking 
time and ability are improved by exercise. The beneﬁ  t of numerous drugs in the treatment of 
IC has been assessed. The results have generally been disappointing, but there is some evidence 
that statins and cilostazol (an inhibitor of phosphodiesterase 3) are of beneﬁ  t. Meta-analyses 
suggest that cilostazol increases maximum walking distance by 40%–50% and improves other 
objective measures of walking. The safety proﬁ  le of cilostazol in patients with PAD appears to 
be acceptable although the mechanism for its effect on IC is unclear. In addition to risk factor 
management, treatment with cilostazol should be considered in patients with disabling IC.
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Peripheral arterial disease (PAD) refers to the pathological process of obstruction of 
the arteries excluding those of the coronary and cerebral circulation. It most commonly 
affects the arteries of the lower limbs and is caused by atherothrombosis or other vascu-
lar disease including embolism, arteritis, and aneurysm. The management of PAD has 
historically focused on preventing local complications such as critical limb ischemia 
and limb loss. More recently there has been a greater emphasis on preventing systemic 
complications of the disease and improving the management of disabling symptoms, 
speciﬁ  cally intermittent claudication (IC). This article will review the medical manage-
ment of PAD in the elderly, with a particular focus on the role of cilostazol in treating 
the symptoms of IC. The management of severe disease causing rest pain or tissue loss 
and needing re-vascularization or amputation will not be reviewed.
Diagnosis of peripheral arterial disease
Intermittent claudication is deﬁ  ned as the painful aching, cramping, or tightness of 
muscles during exercise, due to insufﬁ  cient blood ﬂ  ow to meet the metabolic demands. 
It usually presents in the calf when the infra-inguinal arteries are affected, and may 
also present in the buttocks and thighs if there is aorto-iliac disease. Some patients with 
PAD, particularly the elderly, may not experience IC because of co-morbidities that 
limit walking such as arthritis, spinal stenosis, heart failure, and pulmonary disease 
(McDermott et al 2001). Consequently, a more sensitive diagnostic test for PAD is 
required for the identiﬁ  cation of patients with asymptomatic PAD: the Ankle Brachial 
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The ABPI is deﬁ  ned as the ratio of the highest systolic 
pressure at the ankle divided by the brachial systolic pres-
sure (Naylor et al 1988). It has been widely accepted that 
an ABPI of less than 0.9 is up to 95% sensitive and 99% 
speciﬁ  c in detecting peripheral arterial disease that would be 
detected on angiography (Dormandy and Rutherford 2000; 
Aronow 2004). This non-invasive bedside test is a reliable 
tool in assessing the presence and severity of PAD rather than 
relying solely on a clinical diagnosis. An ABPI of less than 
0.9 is associated with an increased risk of cardiovascular and 
cerebrovascular events (Newman et al 1999). The beneﬁ  t of 
early diagnosis by screening for asymptomatic PAD (deﬁ  ned 
by a ABPI of  0.9), is debated but remains to be established 
(Beckman et al 2006).
Prevalence of peripheral arterial 
disease
The reported prevalence of PAD depends on the diagnostic 
criteria used to deﬁ  ne PAD (Hiatt et al 1995). The prevalence 
of symptomatic and asymptomatic PAD increases markedly 
with age, smoking, and diabetes (Selvin and Erlinger 2004). 
There are weaker associations with male gender, non-white 
ethnicity, hypertension, dyslipidemia, and impaired renal 
function (Norgren et al 2007). The prevalence of IC increases 
from about 2% in those aged 50–54 years to 7% in those aged 
70–74 years (Norgren et al 2007). However, only about one 
third of patients with PAD (deﬁ  ned as an ABPI  0.9) are 
symptomatic with IC (Selvin and Erlinger 2004; Norgren 
et al 2007).
Medical management of peripheral 
arterial disease
The twin priorities in the medical management of PAD are 
symptom relief and the prevention of cardiovascular events. 
Both require treatment of the causes and consequences of 
atherothrombosis but some strategies are more effective for 
one goal than the other.
Smoking cessation
The association between smoking and PAD is very strong 
with over 80% of patients being current or ex-smokers 
(Norgren et al 2007). Furthermore, the association is dose-
dependent; increasing exposure to cigarette smoke is asso-
ciated with earlier onset of symptoms and more severe PAD 
(Fowler et al 2002; Willgendael et al 2004). Finally, smoking 
cessation in patients with PAD is associated with a reduction 
in severity of IC and risk of developing rest pain (Girolami 
et al 1999), albeit to a lesser degree than the reduction in 
risk of coronary heart disease and stroke (Willgendael et al 
2004). This may drive some of the increasing incidence seen 
in the elderly. Rates of smoking cessation are improved by 
such methods as physician advice, nicotine replacement, and 
bupropion therapies (Hankey et al 2006).
Exercise and weight loss
Regular exercise is not only beneﬁ  cial for cardiovascular 
health among the general population (Shepard and Balady 
1999) but also for patients with PAD in whom it reduces 
mortality and cardiovascular events (Garg et al 2006). Exer-
cise is also beneﬁ  cial in improving maximum walking time 
and walking ability (Wind and Koelemay 2007). However, it 
remains to be established whether structured or supervised 
exercise programs are better than unsupervised exercise 
(Fowler et al 2002; Wind and Koelemay 2007). Obesity is 
associated with increased cardiovascular risk (Yusef et al 
2005), but the effectiveness of weight loss in reducing risk 
and improving IC remains to be established.
Dyslipidemia
Epidemiological studies suggest that dyslipidemia is a 
modest risk factor for PAD (Selvin and Erlinger 2004; 
Norgren et al 2007). However, among 2701 patients with a 
history of PAD but no prior coronary heart disease, lowering 
LDL cholesterol by about 1.0 mmol/L by means of simvasta-
tin treatment (40 mg/d) for 5 years resulted in a signiﬁ  cant 
19% reduction in the relative risk of cardiovascular events 
compared with placebo (Heart Protection Study Collabo-
rative Group 2002). Random assignment to simvastatin 
has also been associated with a signiﬁ  cant reduction in the 
incidence of new IC (relative risk 0.62, 95% CI: 0.44–0.88) 
(Pedersen et al 1998) and an improvement in several objec-
tive measures of walking among those who experience IC 
(Erez and Leitersdorf 2007).
Treating hypertension
Hypertension has been reported to be a risk factor for PAD in 
some but not all studies (Selvin and Erlinger 2004; Norgren 
et al 2007). Although there are few data based on patients 
with PAD, drug treatment of hypertension reduces cardio-
vascular risk (Blood pressure lowering treatment trialists’ 
collaboration 2003; Mehler et al 2003). The HOPE study and 
other large trials have established that angiotensin-converting 
enzyme (ACE) inhibitors signiﬁ  cantly reduce the risk of 
cardiovascular related events in patients with symptomatic 
and asymptomatic PAD (Hankey et al 2006; Heart Outcome 
Prevention Evaluation Study Investigators 2000). In addition Clinical Interventions in Aging 2008:3(1) 19
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to the reduction in cardiovascular risk, ACE inhibitors may 
also improve walking distances (Hankey et al 2006).
Treating diabetes
Intermittent claudication is almost twice as common in 
patients with diabetes compared to those with normal 
glycemic control (Norgren et al 2007). Even in the absence 
of diabetes, insulin resistance increases the risk of PAD 
by nearly 50% (Muntner et al 2005). Intensive glycemic 
control reduces the impact of microvascular complications 
of diabetes, but there is little evidence that it changes the 
course of macrovascular disease causing PAD (Adler et al 
2002). Neuropathy, local microvascular changes in the 
foot and PAD all contribute to diabetic foot problems and 
screening for these has been advocated (American Diabetes 
Association 2003).
Antiplatelet therapy
Antiplatelet therapy (chieﬂ  y aspirin) reduces the relative 
risk of major cardiovascular events among those at risk of 
atherothrombosis, including those with IC, by about 25% 
(Antithrombotic Trialists’ Collaboration 2002). Among 
19,000 individuals at high vascular risk randomly assigned 
to long-term aspirin or clopidogrel in the CAPRIE trial, a 
subgroup analysis of the 6000 patients with PAD showed 
that those assigned clopidogrel experienced a 23.8% (95% 
CI: 9%–36%) reduction in the relative risk of major car-
diovascular events compared to aspirin (CAPRIE Steering 
Committee 1996). There is no evidence that aspirin or clo-
pidogrel improve IC.
Role of cilostazol in the treatment 
of intermittent claudication
Over the past three decades there have been numerous trials 
to assess the inﬂ  uence of various drugs on walking distan-
ces and the severity of IC. The majority of these drugs have 
been disappointing and the results of the trials are reviewed 
elsewhere (Hiatt 2001; Aronow 2006). An exception is 
cilostazol, which has emerged over the past decade as a safe 
and effective drug in the management of IC (Thompson 
et al 2002).
Mechanism of action
Cilostazol has antiplatelet and vasodilatory effects which 
are believed to be mediated by inhibition of phosphodie-
sterase 3 (PDE3) which results in increased concentrations 
of intracellular cAMP (Bradbury 2003). Cilostazol inhibits 
primary and secondary platelet aggregation, and high-shear 
stress platelet aggregation both in vivo and in vitro (Reilly 
and Mohler 2001). Shear stress induced during exercise is 
thought to be an important mechanism of platelet activation 
in patients with atherothrombosis and is more effectively 
inhibited by cilostazol than aspirin (Reilly and Mohler 
2001). Cilostazol also increases smooth muscle cell cAMP, 
resulting in a vasodilatory effect which may beneﬁ  t patients 
with IC (Takahashi et al 1992; Matousovic et al 1995; Liu 
et al 2001).
Cilostazol also reduces plasma triglycerides and increases 
plasma HDL concentrations (Elam et al 1998; Beebe et al 
1999; Dawson et al 2000). The mechanism is unclear but it is 
thought to be related to increased levels of cAMP, increased 
lipoprotein lipase activity, and attenuated triglyceride secre-
tion (Motoyashiki et al 1996; Elam et al 1998).
Cilostazol has no effect on the prothrombotic, hypoﬁ  bri-
nolytic state that may develops in patients with IC (Hobbs 
et al 2007).
Despite these insights, the mechanism of action of cilo-
stazol in IC remains uncertain.
The efﬁ  cacy of cilostazol in intermittent 
claudication
There have been a number of trials examining the inﬂ  uence 
of cilostazol on maximal walking distances (MWD), pain 
free walking distance (PFWD), patient’s perception of 
improvement, and plasma lipids. A meta-analysis (Thompson 
et al 2002) identiﬁ  ed 8 phase III randomized, double blind, 
placebo-controlled trials that involved a total of 2702 patients 
with stable, moderate to severe claudication (Table 1). Inclu-
sion criteria were: aged 40 years or older with symptomatic 
PAD for  6 months and no signiﬁ  cant change in severity 
for a minimum of 3 months. Exclusion criteria were: rest 
pain, Buerger’s disease, ischemic tissue necrosis, surgical or 
endovascular procedures within the past 3 months, unstable 
coronary artery disease, symptomatic cardiac arrhythmias, 
recent ( 3 months) DVT, conditions that limited exercise 
capacity other than IC; and usage of  81 mg/day of aspirin 
or 1200 mg/day ibuprofen. Intermittent claudication was 
deﬁ  ned uniformly across all studies as “cramping, aching, 
fatigue, or any patient-reported pain in one or both legs 
that occurred during walking that was sufﬁ  cient to cause 
the subject to reduce the pace or cease ambulation”. An 
ABPI of  0.9 (7 trials) or  0.8 (1 trial) was used to diagnose 
PAD and this was conﬁ  rmed by a decrease of  10 mmHg 
in ankle systolic pressure post exercise. All studies also 
included patients with a decrease in ankle systolic pressure 
greater than 20 mmHg post exercise even if they did not ﬁ  t Clinical Interventions in Aging 2008:3(1) 20
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the ABPI index deﬁ  nition. These patients were then required 
to reproduce exercise ability on 2–3 standardized treadmill 
walking tests with less than 20% variation.
Participants in all studies were assessed with monthly 
medical history, physical examination, blood testing, trea-
dmill testing, Doppler measurements and administration of 
standardised questionaries assessing functional status and 
quality of life. Treadmill tests were either standardised pro-
gressive workload or constant workload formats. All of the 
trials used the percentage change in MWD as their primary 
outcome and the change in PFWD as a secondary outcome. 
Quality of life was assessed using the Medical Outcomes 
Scale Form Health Survey 36 (SF-36) and the Walking 
Impairment Questionnaire (WIQ). The WIQ examined 
walking speed, distance and degree of impairment and was 
used in 6 of the 8 studies.
After exclusion of patients receiving the 150 mg dosing 
(used in one trial only), data from 2399 patients were analy-
zed (Thompson et al 2002). The mean age (years, ± SD) 
of the cilostazol and placebo groups was 65 (±9.24) and 
66 (±8.78) respectively. After treatment for 12–24 weeks, 
there was a statistically significant increase in MWD 
for patients receiving cilostazol 50 mg bd or 100 mg bd 
compared with placebo (increases of 44%, 50%, and 21% 
respectively). Signiﬁ  cant changes in PFWD were seen in 5 
of the 8 trials although there were no differences between 
subgroups based on age, gender, or diabetes. It should be 
noted that the percentage increases in MWD and PFWD 
for the placebo groups highlights the large placebo effect 
in these studies.
The two trials including pentoxifylline showed no 
statistical difference from placebo. After 24 weeks, there 
was a 12.8% increase in high-density lipoprotein chole-
sterol (p = 0.0001) and a 15.8% decrease in triglycerides 
(p = 0.0001) in patients receiving the 100 mg dose compared 
with placebo and pentoxifylline. There were no signiﬁ  cant 
differences in hematological markers, liver function tests, 
renal function, or electrolytes between all three groups 
(Thompson et al 2002).
Regensteiner et al (2002) performed another meta-
analysis on 6 of the 8 studies included in that by Thompson 
et al focusing on the effects of cilostazol (100 mg bd) on 
community based walking ability and quality of life mea-
sures. They believed that treadmill walking did not appro-
priately reﬂ  ect patients’ perceived ability to walk in the 
community and the effect on quality of life. The 6 studies 
Table 1 Randomized controlled trials of cilostazol in patients with PAD including those used in the meta-analysis by Thompson et al 
(2002)
Study  Treatment groups  Participants  Duration (weeks)  Treadmill design
Beebe et al 1999  Cilostazol 50 mg bd  171  24  Constant load
  Cilostazol 100 mg bd  175   
 Placebo  170   
Dawson et al 1998  Cilostazol 100 mg bd  54  12  Constant load
 Placebo  27   
Dawson et al 2000  Cilostazol 100 mg bd  227  24  Variable load
  Pentoxifylline 400 mg tds  232   
 Placebo  239   
Elam et al 1998  Cilostazol 100 mg bd  95  12  Variable load
 Placebo  94   
Hobbs et al 2007  Best Medical Therapy (BMT)  9  24  Constant load
 BMT  + Cilostazol  9   
 BMT  + Cilostazol + Supervised exercise  7   
 BMT  + Supervised exercise  9   
Money et al 1998  Cilostazol 100 mg bd  119  16  Variable load
 Placebo  120   
Otsuka 1996a  Cilostazol 100 mg bd  72  12  Constant load
  Cilostazol 150 mg bd  73   
 Placebo  70   
Otsuka 1996b  Cilostazol 100 mg bd  123  24  Constant load
  Pentoxifylline 400 mg tds  123   
 Placebo  124   
Strandness et al 2002  Cilostazol 50 mg bd  132  24  Constant load
  Cilostazol 100 mg bd  133   
 Placebo  129   
Key: bd, twice daily; tds, three times daily.Clinical Interventions in Aging 2008:3(1) 21
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included all used the SF-36 and the WIQ and the patients 
receiving a dose of 150 mg of cilostazol or pentoxifyl-
line were excluded, bringing the total number to 1751 
(Regensteiner et al 2002). The mean age (years ± SD) of the 
patients analysed in both the cilostazol and placebo groups 
in this meta-analysis was 65 (±9). The WIQ scores were 
signiﬁ  cantly better in patients taking cilostazol compared 
with placebo. The physical summary score on the SF-36 
improved 5% in those patients taking cilostazol along with 
increases in the subscale scores of physical functioning, 
limitations/problems, and bodily pain. However, patients 
taking placebo also improved their physical function score 
signiﬁ  cantly (p   0.05), albeit to a lesser degree than that 
seen with cilostazol. It was concluded that the WIQ and the 
SF-36 appropriately reﬂ  ected increases in MWD and PFWD 
through examining patients’ perceived ability to walk in a 
community based setting and their health related quality of 
life (Regensteiner et al 2002).
Further evidence of the efﬁ  cacy of cilostazol was demon-
strated in a study involving 59 patients randomized to cilo-
stazol or pentoxifylline and then crossed over to placebo for 
6 weeks of treatment. Patients receiving cilostazol lost 49% 
of the increased MWD after 24 weeks of treatment when 
the drug was stopped, an effect not seen with pentoxifylline 
(Dawson 2001).
Three randomized controlled trials involving cilostazol 
examined its effect on ABPI with mixed results. Money et al 
(1998), whose study involved 239 patients found that was a 
marginal increase in ABPI in the cilostazol group (0.64 ± 0.02 
to 0.7 ± 0.02) compared with the placebo group (0.68 ± 0.02 
to 0.69 ± 0.02). Other studies also showed extremely modest 
improvements in ABPI, without any statistical signiﬁ  cance 
(Dawson et al 1998; Hobbs et al 2007).
Dose response relationship
Beebe et al 1999 analyzed the data from 516 patients rando-
mized to 1 of 3 groups: cilostazol 50 mg twice daily, cilostazol 
100 mg twice daily, or placebo (Beebe et al 1999). Patients 
in this trail were tested on a constant grade treadmill with a 
grade of 12.5% and at a speed of 3.2 km/h. Patients receiving 
50 mg twice daily increased their walking distances by almost 
1.5 fold (MWD from 132 m to 199 m and PFWD from 67 m 
to 115 m at 24 weeks). This increase was proportionately 
larger in those receiving cilostazol 100 mg twice daily with 
an almost 2-fold increase (MWD from 130 m to 259 m and 
PFWD from 70 m to 138 m at 24 weeks) (Beebe et al 1999). 
Using extrapolations based on energy expenditure, it has been 
estimated that patients taking cilostazol 50 mg twice daily 
would double their walking distances and those receiving 
cilostazol 100 mg twice daily would triple their maximal 
walking distances (Cariski 2001).
Use in diabetic patients
The efﬁ  cacy of cilostazol (100 mg twice daily) in diabe-
tic patients has been reviewed by Rendell et al (2002). 
Using data from 8 trials, 216 diabetic patients and 599 
non-diabetic patients receiving cilostazol were compared 
with 220 diabetic and 616 non-diabetic patients receiving 
placebo. There was no signiﬁ  cant difference in increased 
percentage of MWD (51% vs 61%) between the diabetic 
and non-diabetic patients treated with cilostazol. Among 
patients with more severe claudication (shortest baseline 
MWD) those with diabetes experienced a greater percen-
tage increase in MWD with cilostazol than those without 
diabetes (34% change from baseline MWD in Q1 compared 
with 5.5%, 23% and 17.2% in Q2, Q3, Q4, log transformed 
data) (Rendell et al 2002).
Safety and side effect proﬁ  le
Pratt reviewed the safety data from the 8 randomized control 
trials in an analysis that included 1374 patients receiving 
cilostazol for 12–24 weeks (475 patient exposure years) 
(Pratt 2001). The most common side effects associated with 
cilostazol were headache, diarrhoea, and other gastrointesti-
nal complaints; 1.3% of patients on cilostazol 50 mg twice 
daily and 3.7% on 100 mg twice daily had to discontinue the 
drug due to headache compared with only 0.3% of patients 
on placebo. The rate of cardiovascular events including 
myocardial infarction and stroke were similar in all three 
of the groups (Pratt 2001). Exacerbation of pre-existing 
cardiac failure in was similar (5.5% vs 4.8%) with cilosta-
zol (n = 55) and placebo (n = 42). Very few patients treated 
with cilostazol (7/973, 0.72%) developed new onset heart 
failure compared with those on placebo (12/1374, 0.87%) 
(Pratt 2001). However, cilostazol remains contraindicated in 
patients with heart failure.
Conclusion
The management of PAD and IC are important issues for 
all clinicians treating the aging population. Early diagnosis 
and optimal medical management has the potential to pro-
vide patients with the best quality and longevity of life. The 
emergence of cilostazol as a pharmacological treatment of IC 
has added a further option to the clinician’s armamentarium 
in managing these patients. Cilostazol increases maximal 
walking distance, pain free walking distance, and quality of Clinical Interventions in Aging 2008:3(1) 22
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life and is superior to other medical options for treatment 
of IC. It is contraindicated in patients with heart failure but 
is safe in the elderly and diabetic patients and has a tolera-
ble side effect proﬁ  le. Cilostazol is available in 50 mg and 
100 mg preparations in both the US and UK markets.
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